Golden
Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics

Biopharmaceutical company focused on exploring effects of cytokine based therapies on cancer.

Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company that is focused on exploring the role that cytokine-based therapies can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer treatments.



The company's leading product candidate is IRX-2, a cytokine based therapy. It delivers IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, thereby enabling the immune system to attack cancer cells. In a Phase 2A clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which is associated with a survival benefit in patients with head and neck cancer. Brooklyn ImmunoTherapeutics has initiated a Phase 2B clinical study of IRX-2 in patients with squamous cell cancer of the head and neck, with results expected to be reported in 2020.



The company is also exploring the potential of IRX-2 in other oncology indications in collaboration with multiple pharmaceutical companies. Clinical trials in combination with other anti-cancer agents such as checkpoint inhibitors are also being conducted. 

Timeline

People

Name
Role
LinkedIn

Lynn Sadowski Mason

VP, Clinical Operations



Mark Leuchtenberger

Interim CEO



Michael Wyand

Senior Technical Advisor



Monil Shah

COO



Ron Guido

Senior VP, Regulatory Affairs and Quality Systems



Further reading

Title
Author
Link
Type
Date

Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

Business Wire

Web



Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

Business Wire

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References